27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Evidence suggests that delirium is associated with long-term poor outcome but delirium often occurs in individuals with more severe underlying disease. 5 key findings →
Design: meta-analysis Participants: 714 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. 5 key findings →
Participants: 102 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Two loci were identified to have genome-wide significance for the first time: rs744373 near BIN1 (odds ratio [OR],1.13; 95% confidence interval [CI],1.06-1.21 per copy of the minor allele; P = 1.59x10(-11)) and rs597668 near EXOC3L2/BLOC1S3/MARK4 (OR, 1.18; 95% CI, 1.07-1.29; P = 6.45x10(-9)). 3 key findings →
Participants: 35,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P = 0.001). 2 key findings →
Design: randomized controlled trial Participants: 271 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Hypertension significantly increases the risk of vascular dementia. 4 key findings →
Design: meta-analysis Participants: 768 Evidence: high
Full summary, score breakdown and related studies → Original source
Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. 3 key findings →
Participants: 485 Evidence: high
Full summary, score breakdown and related studies → Original source
Six months of high-intensity aerobic exercise had sex-specific effects on cognition, glucose metabolism, and hypothalamic-pituitary-adrenal axis and trophic activity despite comparable gains in cardiorespiratory fitness and body fat reduction. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Exogenous low dose melatonin administered nightly to elderly patients admitted to acute care may represent a potential protective agent against delirium. 3 key findings →
Participants: 145 Evidence: high
Full summary, score breakdown and related studies → Original source
In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. 4 key findings →
Design: randomized controlled trial Participants: 640 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
PBT2 is a copper/zinc ionophore that rapidly restores cognition in mouse models of Alzheimer's disease (AD). 4 key findings →
Design: post-hoc analysis Evidence: high
Full summary, score breakdown and related studies → Original source
The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation. 3 key findings →
Design: randomized controlled trial Participants: 114 Evidence: high
Full summary, score breakdown and related studies → Original source
Our data show that elderly patients with DM without dementia have accelerated progression of brain atrophy with significant consequences in cognition compared to subjects without DM. 5 key findings →
Design: randomized controlled trial Participants: 89 Evidence: high
Full summary, score breakdown and related studies → Original source
No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-ε4-negative or other analysis populations. 2 key findings →
Design: open-label trial Participants: 693 Evidence: high
Full summary, score breakdown and related studies → Original source
We investigated the effects of renin-angiotensin system blockade on cognitive function in patients aged 55 years and older with established atherosclerotic cardiovascular disease or diabetes with end-organ damage in two clinical trials. 4 key findings →
Design: randomized controlled trial Participants: 620 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients with MCI converted to AD at an annual rate of 17.2%. 2 key findings →
Design: longitudinal study Participants: 85 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Reductions in cerebral glucose metabolic rate (CMRglu) as measured by fludeoxyglucose F 18-positron emission tomography (FDG-PET) in parietotemporal, frontal, and cingulate cortices are associated with increased AD risk and can be observed years before dementia onset. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among community-living dyads, a nonpharmacologic biobehavioral environmental intervention compared with control resulted in better outcomes for COPE dyads at 4 months. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This systematic literature review addressed the efficacy of 15 cognitive intervention programs that have been tested in individuals presenting with mild cognitive impairment of the amnestic type (MCI-A) possibly at risk to progress toward dementia. 2 key findings →
Participants: 193 Evidence: high
Full summary, score breakdown and related studies → Original source
Sertraline did not demonstrate efficacy for the treatment depression symptoms in patients with AD. 2 key findings →
Participants: 67 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
During a mean (SD) follow-up of 6.1 (3.2) years, 1601 participants had no hospitalization, 1287 had 1 or more noncritical illness hospitalizations, and 41 had 1 or more critical illness hospitalizations. 4 key findings →
Design: cohort study Participants: 2,929 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
(18)F-Flutemetamol performs similarly to the (11)C-PIB parent molecule within the same subjects and provides high test-retest replicability and potentially much wider accessibility for clinical and research use. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
No significant differences were noted between the two treatments in patients with PDD (3·6 with memantine vs 3·8 with placebo, -0·1 [-0·6 to 0·3]; p=0·576) or in the total population (3·5 with memantine vs 3·8 with placebo, -0·3 [-0·7 to 0·1]; p=0·120). 4 key findings →
Participants: 199 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Main results Outcome data were available in 202 out of 234 included trials, investigating 60 clinical conditions. 1 key finding →
Participants: 6,041 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Pioglitazone was generally well tolerated in this pilot study. 2 key findings →
Design: randomized controlled trial Participants: 29 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Increasing crystallised intelligence and fruit and vegetable consumption and eliminating depression and diabetes are likely to have the biggest impact on reducing the incidence of dementia, outweighing even the effect of removing the principal known genetic risk factor. 2 key findings →
Design: cohort study Participants: 1,433 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →